Items where authors include "Coffey, M"
Article
Schuelke, MR, Gundelach, JH, Coffey, M et al. (7 more authors) (2022) Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors. Neuro-Oncology Advances, 4 (1). pp. 1-10. ISSN 2632-2498
Wantoch, M, Wilson, EB orcid.org/0000-0002-0441-728X, Droop, AP et al. (7 more authors) (2022) Oncolytic virus treatment differentially affects the CD56ᵈⁱᵐ and CD56ᵇʳⁱᵍʰᵗ NK cell subsets in vivo and regulates a spectrum of human NK cell activity. Immunology, 166 (1). pp. 104-120. ISSN 0019-2805
Müller, LME, Migneco, G, Scott, GB et al. (17 more authors) (2021) Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer, 9 (3). e001803. ISSN 2051-1426
Schuelke, MR, Wongthida, P, Thompson, J et al. (8 more authors) (2019) Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity. Journal for ImmunoTherapy of Cancer, 7 (1). 188. ISSN 2051-1426
Berkeley, RA, Steele, LP, Mulder, AA et al. (8 more authors) (2018) Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy. Cancer Immunology Research, 6 (10). pp. 1161-1173. ISSN 2326-6066
Samson, A orcid.org/0000-0002-3081-7850, Bentham, MJ orcid.org/0000-0003-2439-3198, Scott, K orcid.org/0000-0002-5790-9579 et al. (15 more authors) (2018) Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut, 67 (3). pp. 562-573. ISSN 0017-5749
Kottke, T, Evgin, L, Shim, KG et al. (12 more authors) (2017) Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence. Cancer Immunology Research, 5 (11). pp. 1029-1045. ISSN 2326-6066
Ilett, E, Kottke, T, Thompson, J et al. (12 more authors) (2017) Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumor therapy. Gene Therapy, 24 (1). pp. 21-30. ISSN 0969-7128
Rajani, K, Parrish, C, Kottke, T et al. (10 more authors) (2016) Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Molecular Therapy, 24 (1). pp. 166-174. ISSN 1525-0016
Parrish, C, Scott, GB, Migneco, G et al. (13 more authors) (2015) Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia, 29 (9). 1799 - 1810. ISSN 0887-6924
Roulstone, V, Pedersen, M, Kyula, J et al. (14 more authors) (2015) BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Molecular Therapy, 23 (5). pp. 931-942. ISSN 1525-0016
El-Sherbiny, YM, Holmes, TD, Wetherill, LF et al. (12 more authors) (2015) Controlled infection with a therapeutic virus defines the activation kinetics of human natural killer cells in vivo. Clinical and experimental immunology, 180 (1). pp. 98-107. ISSN 0009-9104
Roulstone, V, Khan, K, Pandha, HS et al. (8 more authors) (2015) Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clinical Cancer Research, 21 (6). 1305 - 1312. ISSN 1078-0432
Ilett, E orcid.org/0000-0002-9875-0322, Kottke, T, Donnelly, O et al. (10 more authors) (2014) Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus. Molecular Therapy, 22 (10). pp. 1851-1863. ISSN 1525-0016
Jennings, V, Ilett, EJ orcid.org/0000-0002-9875-0322, Scott, K orcid.org/0000-0002-5790-9579 et al. (10 more authors) (2014) Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. International Journal of Cancer, 134 (5). pp. 1091-1101. ISSN 0020-7136
Kottke, T, Boisgerault, N, Diaz, RM et al. (12 more authors) (2013) Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nature Medicine, 19. 1625 - 1631. ISSN 1078-8956
Twigger, K, Roulstone, V, Kyula, J et al. (14 more authors) (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 12. 368. ISSN 1471-2407
Hall, K, Scott, KJ, Rose, A et al. (9 more authors) (2012) Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia. BioResearch Open Access, 1 (1). pp. 3-15. ISSN 2164-7844
Steele, L, Errington, F orcid.org/0000-0003-2155-534X, Prestwich, R et al. (7 more authors) (2011) Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming. Molecular Cancer, 10 (1). 20. ISSN 1476-4598